Aytu Biopharma, Inc.
AYTU
$2.17
-$0.04-1.81%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.38M | 65.84M | 61.41M | 63.94M | 65.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.38M | 65.84M | 61.41M | 63.94M | 65.18M |
| Cost of Revenue | 20.55M | 19.21M | 17.23M | 15.94M | 16.13M |
| Gross Profit | 45.83M | 46.63M | 44.18M | 48.00M | 49.05M |
| SG&A Expenses | 38.29M | 39.26M | 40.14M | 40.44M | 42.04M |
| Depreciation & Amortization | 3.68M | 3.68M | 3.68M | 3.68M | 3.68M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.85M | 64.30M | 63.65M | 62.65M | 64.62M |
| Operating Income | 2.54M | 1.54M | -2.24M | 1.29M | 565.00K |
| Income Before Tax | -13.75M | 3.16M | -2.42M | -1.41M | -10.38M |
| Income Tax Expenses | 437.00K | 841.00K | 1.48M | 2.55M | 2.14M |
| Earnings from Continuing Operations | -14.18 | 2.32 | -3.91 | -3.95 | -12.52 |
| Earnings from Discontinued Operations | 620.00K | -681.00K | -1.33M | -2.30M | -3.32M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.56M | 1.64M | -5.24M | -6.25M | -15.84M |
| EBIT | 2.54M | 1.54M | -2.24M | 1.29M | 565.00K |
| EBITDA | 7.91M | 7.18M | 3.62M | 7.60M | 7.29M |
| EPS Basic | -1.90 | 0.20 | -0.97 | -1.14 | -2.86 |
| Normalized Basic EPS | -0.23 | 0.79 | 0.23 | 0.22 | -0.87 |
| EPS Diluted | -3.13 | -1.04 | -1.76 | -1.54 | -2.87 |
| Normalized Diluted EPS | -0.46 | 0.57 | 0.11 | 0.14 | -0.87 |
| Average Basic Shares Outstanding | 25.13M | 23.95M | 23.35M | 22.74M | 22.15M |
| Average Diluted Shares Outstanding | 32.58M | 31.41M | 28.74M | 25.77M | 22.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |